121 related articles for article (PubMed ID: 31688398)
1. Duloxetine-Associated Acute Laryngeal Dystonia: A Case Report.
Dagklis IE; Rokkou I; Kazis D; Bostantjopoulou S
J Clin Psychopharmacol; 2019; 39(6):678-679. PubMed ID: 31688398
[No Abstract] [Full Text] [Related]
2. Acute Urinary Retention and Acute Kidney Injury After Duloxetine Treatment: A Rare Case Report.
Aktürk Esen S; Gül CB; Kahvecioğlu S; Aktaş N; Esen İ
J Clin Psychopharmacol; 2019; 39(3):279-281. PubMed ID: 30908353
[No Abstract] [Full Text] [Related]
3. A probable case of movement disorder (Tardive dyskinesia) due to duloxetine treatment.
Yılmaz R; Üstün D; Tuncer Uzun S; Reisli R; Türk Ş
Agri; 2018 Oct; 30(4):199-201. PubMed ID: 30403275
[TBL] [Abstract][Full Text] [Related]
4. First-Trimester Pregnancy Exposure to Venlafaxine or Duloxetine and Risk of Major Congenital Malformations: A Systematic Review.
Lassen D; Ennis ZN; Damkier P
Basic Clin Pharmacol Toxicol; 2016 Jan; 118(1):32-6. PubMed ID: 26435496
[TBL] [Abstract][Full Text] [Related]
5. Responsibility of the doctor who prescribes serotonin and noradrenaline reuptake inhibitors for patients with chronic musculoskeletal pain.
Nagamine T
Psychiatry Clin Neurosci; 2018 Jan; 72(1):45-46. PubMed ID: 29064131
[No Abstract] [Full Text] [Related]
6. Duloxetine, a serotonin and norepinephrine reuptake inhibitor, may be a double-edged sword for patients with advanced Parkinson's disease.
Nagamine T
Asian J Psychiatr; 2020 Apr; 50():102031. PubMed ID: 32272360
[No Abstract] [Full Text] [Related]
7. [Duloxetine Associated Galactorrhea and Hyperprolactinemia: A Case Report].
Özkan HM
Turk Psikiyatri Derg; 2020; 31(4):294-296. PubMed ID: 33454942
[TBL] [Abstract][Full Text] [Related]
8. Duloxetine and gingival bleeding: a case-report and reviews of the French and World PharmacoVigilance Databases and literature.
Gicquel C; Moulis F; Chenaf C; Gouraud A; Drici M; Bondon-Guitton E; Montastruc F; Montastruc JL
Eur J Clin Pharmacol; 2017 Sep; 73(9):1197-1198. PubMed ID: 28639120
[No Abstract] [Full Text] [Related]
9. Duloxetine in elderly major depression disorder: effectiveness and drug plasma level evaluation.
Rovera C; Mauri MC; Bertin E; Di Pace C; Paletta S; Reggiori A; De Gaspari IF; Cattaneo D; Mari D; Altamura AC
Hum Psychopharmacol; 2016 Sep; 31(5):349-55. PubMed ID: 27400882
[TBL] [Abstract][Full Text] [Related]
10. The Effect of Food on the Single-Dose Bioavailability and Tolerability of the Highest Marketed Strength of Duloxetine.
Rizea-Savu S; Duna SN; Ghita A; Iordachescu A; Chirila M
Clin Pharmacol Drug Dev; 2020 Oct; 9(7):797-804. PubMed ID: 31793229
[TBL] [Abstract][Full Text] [Related]
11. How Does Usage of Serotonin Noradrenaline Reuptake Inhibitors Affect Intraocular Pressure in Depression Patients?
Uçan Gündüz G; Parmak Yener N; Kılınçel O; Gündüz C
J Ocul Pharmacol Ther; 2018 May; 34(4):354-359. PubMed ID: 29446702
[TBL] [Abstract][Full Text] [Related]
12. Dysosmia and dysgeusia associated with duloxetine.
Yoshida K; Fukuchi T; Sugawara H
BMJ Case Rep; 2017 Nov; 2017():. PubMed ID: 29170185
[TBL] [Abstract][Full Text] [Related]
13. Syndrome of inappropriate antidiuretic hormone secretion: a story of duloxetine-induced hyponatraemia.
Amoako AO; Brown C; Riley T
BMJ Case Rep; 2015 Apr; 2015():. PubMed ID: 25911354
[TBL] [Abstract][Full Text] [Related]
14. An Open-Label Pilot Study of Duloxetine in Patients With Irritable Bowel Syndrome and Comorbid Major Depressive Disorder.
Lewis-Fernández R; Lam P; Lucak S; Galfalvy H; Jackson E; Fried J; Rosario M; de la Cruz AA; Sánchez-Lacay A; Díaz S; Schneier F
J Clin Psychopharmacol; 2016 Dec; 36(6):710-715. PubMed ID: 27755218
[TBL] [Abstract][Full Text] [Related]
15. Antidepressants May Make for Depressing Surgery.
Oberg TJ; Eftekhari K; Anderson RL
Ophthalmic Plast Reconstr Surg; 2015; 31(4):334. PubMed ID: 26164037
[No Abstract] [Full Text] [Related]
16. Steroidogenic disruptive effects of the serotonin-noradrenaline reuptake inhibitors duloxetine, venlafaxine and tramadol in the H295R cell assay and in a recombinant CYP17 assay.
Islin J; Munkboel CH; Styrishave B
Toxicol In Vitro; 2018 Mar; 47():63-71. PubMed ID: 29100959
[TBL] [Abstract][Full Text] [Related]
17. Recurrent thunderclap headaches from reversible cerebral vasoconstriction syndrome associated with duloxetine, xylometazoline and rhinitis medicamentosa.
Pham H; Gosselin-Lefebvre S; Pourshahnazari P; Yip S
CMAJ; 2020 Nov; 192(45):E1403-E1406. PubMed ID: 33168762
[No Abstract] [Full Text] [Related]
18. Duloxetine lessens joint pain in early-stage breast cancer.
Tanday S
Lancet Oncol; 2017 Jan; 18(1):e10. PubMed ID: 27989429
[No Abstract] [Full Text] [Related]
19. Differential inhibition of cardiac and neuronal Na(+) channels by the selective serotonin-norepinephrine reuptake inhibitors duloxetine and venlafaxine.
Stoetzer C; Papenberg B; Doll T; Völker M; Heineke J; Stoetzer M; Wegner F; Leffler A
Eur J Pharmacol; 2016 Jul; 783():1-10. PubMed ID: 27130441
[TBL] [Abstract][Full Text] [Related]
20. Mixed lymphocytic and collagenous inflammation of the entire gastrointestinal tract under therapy with serotonin and norepinephrine reuptake inhibitors.
Varelas AI; Fürst S; Langner C
Virchows Arch; 2022 Nov; 481(5):779-783. PubMed ID: 35655103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
